LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/eve...
LivaNova offers strong medtech upside with market-leading positions in cardiac surgery and neuromodulation, but lacks a dividend yield. Recent results show double-digit organic growth, margin expansion, and a positive sales trajectory, especially in Cardiopulmonary. Valuation is attractive: at a discounted 17x P/E, I see 20%+ annual upside and limited downside risk at current prices.
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.
LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.
LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties...
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis ...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.